AcelRx Pharmaceuticals, Inc. (ACRX)
| Market Cap | 12.46M |
| Revenue (ttm) | 622,000 |
| Net Income (ttm) | -26.48M |
| Shares Out | 16.95M |
| EPS (ttm) | -2.97 |
| PE Ratio | n/a |
| Forward PE | 1.06 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 919,994 |
| Open | 0.810 |
| Previous Close | 0.819 |
| Day's Range | 0.721 - 0.858 |
| 52-Week Range | 0.430 - 2.780 |
| Beta | 0.64 |
| Analysts | Strong Buy |
| Price Target | 4.63 (+529.93%) |
| Earnings Date | Nov 8, 2023 |
About ACRX
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for ... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ACRX stock is "Strong Buy." The 12-month stock price forecast is $4.63, which is an increase of 529.93% from the latest price.
News
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States
Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonstrate challenges physicians have with heparin and citrate, the two currently available CRRT antic...
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter with topline data expected mid-2024 Cash ...
AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical Study
Two KOLs will discuss recent quantitative market research on the use of anticoagulants in the dialysis circuit Discussion will also focus on the Niyad study protocol for upcoming NEPHRO Study Register...
AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023
HAYWARD, Calif. , Oct. 26, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative...
AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study
Investigational Device Exemption (IDE) approval by the U.S. Food and Drug Administration (FDA) allows AcelRx to begin pivotal study of Niyad™ Single registration study with pre-agreed upon endpoints p...
AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference
SAN MATEO, Calif. , Sept. 6, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovati...
AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Capital raise closed in July, led by new healthcare investors; provides access to up to $26.3 million in capital, with $10 million immediately available AcelRx awaits response to Emergency Use Authori...
AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023
HAYWARD, Calif. , July 27, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative...
AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules
Transformative capital raise, led by new investors including Nantahala Capital Management The private placement provides access to up to $26.3 million of gross proceeds upon the exercise of the mile...
AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
Upon the achievement of certain milestones accelerating the warrants' expiration date, AcelRx may receive an additional $16.3 million of gross proceeds if the common warrants are exercised in full HAY...
AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
Request for Emergency Use Authorization of Niyad™ submitted to the FDA in April Divestment of DSUVIA® to Alora Pharmaceuticals closed April 3, 2023 $13.4 million in cash as of March 31, 2023 Webcast a...
AcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023
HAYWARD, Calif. , April 27, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapie...
AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals
In connection with closing, AcelRx received approximately $2.7 million from Alora Pharmaceuticals and Aguettant AcelRx announces full repayment of its senior loan with Oxford Finance HAYWARD, Calif. ,...
AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update
Divestment of DSUVIA® to Alora Pharmaceuticals expected to close the week of April 3, 2023 AcelRx advancing its proprietary Niyad™ nafamastat program with FDA Breakthrough designation in line with a s...
AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023
HAYWARD, Calif. , March 21, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapie...
AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals
Agreement with Alora Pharmaceuticals provides AcelRx with 15% royalties on commercial sales, 75% royalties on Department of Defense (DoD) sales, up to $116.5 million in potential sales-based milestone...
AcelRx Pharmaceuticals Announces Peer-Reviewed Publication On the Use of DSUVIA® For In-Office Rhinology Procedures
Study is the first to report on the use of DSUVIA® in the rapidly growing field of rhinology where otolaryngologists are performing painful nasal and sinus procedures in the office which were historic...
AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock
HAYWARD, Calif. , Dec. 27, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative ...
Three Healthcare Penny Stocks to Watch In The New Year
These three penny (and nickel) stocks in the healthcare sector have a lot of potential for 2023, and definitely worth watching.
AcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical Medicine
Patients reported lower pain scores, required fewer rescue doses and had a shorter hospital stay than patients receiving continuous femoral nerve block This study of patients following knee replacemen...
AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Initial Niyad development batch successfully produced; preparations on track for an Emergency Use Authorization submission DSUVIA sales of $0.5M in the third quarter, a 217% increase over prior year $...
AcelRx to Host Third Quarter 2022 Financial Results Call and Webcast on November 14, 2022
HAYWARD, Calif. , Nov. 3, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company, today announced that it will release third quarter financial ...
AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022
The study of 324 complex plastic surgery procedures demonstrated many benefits of using DSUVIA for analgesia, including avoiding the need for general anesthesia HAYWARD, Calif. , Oct. 31, 2022 /PRNews...
AcelRx Pharmaceuticals Announces the European Launch of DZUVEO by its Partner, Aguettant
Physicians across Europe will now have access to DZUVEO®, a novel sublingual approach to acute pain management in medically supervised settings HAYWARD, Calif. , Oct. 27, 2022 /PRNewswire/ -- AcelRx P...
AcelRx Pharmaceuticals Announces Presentation of Investigator-Initiated Trial Results Comparing AcelRx's Sufentanil Sublingual Tablet (SST) Versus Intravenous Opioids for Postoperative Pain at the ANESTHESIOLOGY® Annual Meeting 2022
Brigham and Women's Hospital study found that SST-treated patients had significantly lower pain scores in the post-operative care unit (PACU) compared with patients in the two intravenous opioid contr...